How useful is HPV-DNA test for screening of cervical cancer: a prospective study

Vineeta Gupta, Archana Tandon, Neeta Bansal, Anuja Nanda


Background: The aim of present study was to evaluate the utility of HPV-DNA testing in cervical cancer screening.

Methods: The study included 110 women presenting to the Gynaecological OPD of SMI Hospital who were subjected to HPV DNA test and one or more of other tests like cytology, colposcopy and histopathological examination. The results were evaluated by standard statistical methods.

Results: Out of 110 patients in whom HPV-DNA testing was done, 24 had positive result, 83 had negative result and 3 had borderline test result. Sensitivity & Specificity of HPV-DNA testing was calculated to be 90% and 84.61% respectively. Its positive predictive value and negative predictive value were 69.23% and 95.66%. The percentage of false negative was calculated to be 10% and that of false positive was 15.38%.

Conclusions: In our study, the sensitivity and negative predictive value of HPV-DNA testing was found to be more as compared to its specificity and positive predictive value. Widespread HPV testing for primary cervical cancer screening is not recommended as it will increase the volume of HPV testing and will not be cost- effective. It may be used for secondary screening in patients with abnormal or (ASC) cytology results as this will help in their subsequent management.


HPV-DNA test, Cervical cancer screening

Full Text:



IARC Handbooks of cancer prevention. Vol 10. Cervix cancer screening. IARC press, Lyon. 2005.

Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV Testing with cytology Triage and/or Repeat HPV DNA Testing in Primary cervical cancer Screening. JNCI Journal of the National Cancer Institute. 2009;101(2):88-99.

Pajtler M, Milicic-Juhas V, Milojkovic M, Topolovec Z, Curzik D, Mihaljevic I. Assessment of HPV DNA test value in management of women with cytological findings of ASC-US, CIN 1 and CIN 2. Coll Antropol. 2010;34(1):81-6.

Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S. HPV DNA testing in cervical cancer screening: results from women in a high risk province of Costa-Rica. JAMA. 2000;283(1):87-93.

The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. I Natl Cancer Inst. 2000;92:397-402.

Sigurdsson K, Amadottir T, Snorrad M, Benediktsdottir K, Saemundsson H. Human papillomavirus (HPV) in an Icelandic population: The role of HPV DNA testing based on hybrid capture and PCR assays among women with screen detected abnormal pap smears. Int J Cancer. 1997:72:446-52.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Jen Shies-Negi, Kurman RJ, et al. Identifying women with Cervical Neoplasia. JAMA. 1999;281:1605-10.

Leinonen M, Nieminen P, Kotaniemi- Talonen L, Malila N, Tarkkanen J, Laurila P. Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting. J Natl Cancer Inst. 2009;101:1612-23.

Kulasingam SL, Hughes JP, Kiviat NB. Evaluation of human papillomavirus tasting in primary screening for cervical abnormalities. JAMA. 2002;288:1749-57.

Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8.

Wheeler CM, Greer CE, Becker TM, Hunt WC. Anderson SM, Manos MM. Short-term fluctutions in the detection of cervical human papillomavirus DNA. Obstet Gynecol. 1996

Bhatla N, Moda N. The clinical utility of HPV-DNA testing in cervical cancer screening strategies. Indian J Med Res. 2009;130:261-5.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG. Baseline cyrology human papillomavirus testing and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.